Compare Ascendis Pharma A/S (ASND) vs Deere & Company (DE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Deere & Company — how do they compare? Ascendis Pharma A/S trades at $265.85 (market cap $17.74B), while Deere & Company trades at $586.28 (market cap $158.42B). The key difference: Deere & Company is far larger — about 8.9× Ascendis Pharma A/S's market cap, and Deere & Company pays a 1.1% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | DE | |
|---|---|---|
Market Cap | $17.74B | $158.42B |
Sector | Health | Industrials |
52-Week High | $277.18 | $662.49 |
52-Week Low | $163.32 | $439.11 |
Enterprise Value | $18.11B | $213.24B |
Dividend Yield | — | 1.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Deere & Company (DE) trades at $586.86, down 1.02% on the day, near the lower end of its 52-week range. The stock shows a bullish technical signal with recent earnings beats but faces revenue declines from $60.2B in 2023 to $44.7B in 2025. Analyst consensus is mixed with a $689.30 price target, and the company maintains strong cash flow from operations of $7.46B in 2025.
The outlook hinges on agricultural sector recovery and precision farming growth, offering potential upside if earnings stabilize. Risks include cyclical demand, high debt levels, and margin pressure from declining net income. Investor sentiment is cautious amid volatile farm economics, yet institutional holdings suggest long-term confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →
